Protease inhibitors and cardiovascular disease: Analysis of the Los Angeles County adult spectrum of disease cohort

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 19, Issue 4, 2007, Pages 492-499

  Vaughn, G ^a   Detels, R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; CORONARY ARTERY DISEASE; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTERNATIONAL CLASSIFICATION OF DISEASES; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TIME; UNITED STATES;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INCIDENCE; LOS ANGELES; MALE; MIDDLE AGED; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 34247173460     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540120701203329     Document Type: Article

References (24)

1. Behrens, G., Dejam, A., Schmidt, H., Balks, H.J., Brabant, G., Korner, T., Stoll, M., & Schmidt, R.E. (1999). Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS, 13, F63-F70.
2. Berthold, H.K., Parhofer, K.G., Ritter, M.M., Addo, M., Wasmuth, J.C., Schliefer, K., Spengler, U., & Rockstroh, J.K. (1999). Influence of protease inhibitor therapy on lipoprotein metabolism. Journal of Internal Medicine, 246, 567-75.
3. Bozzette, S.A., Ake, C.F., Tam, H.K, Chang, S.W., & Louis, T.A. (2003). Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. New England Journal of Medicine, 348, 702-10.
4. Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D.J., & Cooper, D.A. (1998a). A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS, 12, F51-F58.
5. Carr, A., Samaras, K., Chisholm, D.J., & Cooper, D.A. (1998b). Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet, 351, 1881-83.
6. Danner, S.A., Carr, A., Leonard, J.M., Lehman, L.M., Gudiol, F., Gonzales, J., Raventos, A., Rubio, R., Bouza, E., & Pintado, V. (1995). A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. New England Journal of Medicine, 333, 1528-33.
7. Detels, R., Muñoz, A., McFarlane, G., Kingsley, L.A., Margolick, J., Giorgi, J., Schrager, L.K., & Phair, J.P. (1998). Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA, 280(17), 1497-503.
8. Dube, M.P., Stein, J.H., Aberg, J.A., Fichtenbaum, C.J., Gerber, J.G., Tashima, K.T., Henry, W.K., Currier, J.S., Sprecher, D., & Glesby, M.J. (2003). Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clinical Infectious Diseases, 37, 613-27.
9. Farizo, K.M., Buehler, J.W., Chamberland, M.E., Whyte, B.M., Froelicher, E.S., Hopkins, S.G., Reed, C.M., Mokotoff. E.D., Cohn, D.L., & Troxler, S. (1992). Spectrum of disease in persons with human immunodeficiency virus infection in the United States. Journal of the American Medical Association, 267, pp.1798-805.
10. Friis-Moller, N., Weber, R., Reiss, P., Thiebaut, R., Kirk, O., d'Arminio Monforte, A., Pradier, C., Morfeldt, L., Mateu, S., Law, M., El-Sadr, W., De Wit, S., Sabin, C.A., Phillips, A.N., Lundgren, J.D. For the Dad Study Group (2003). Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS, 17, pp. 1179-93.
11. Friis-Moller, N., Sabin, C.A., Weber, R., d'Arminio Monforte, A., El-Sadr, W.M., Reiss, P., Thiebaut, R., Morfeldt, L., De Wit, S., Pradier, C., Calvo, G., Law, M.G., Kirk, O., Phillips, A.N., Lundgren, J.D.; Data collection on adverse events of anti-HIV drugs (Dad) Study Group (2003). Combination antiretroviral therapy and the risk of myocardial infarction. New England Journal of Medicine, 349, 1993-2003.
12. HIV Epidemiology Program, Los Angeles County Department of Health Services (2001). Adult and Adolescent Spectrum of HIV Disease (ASD) Semi-Annual Summary Report.
13. Iloeje, U.H., Yuan, Y., L'italien, G., Mauskopf, J., Holmberg, S.D., Moorman, A.C., Wood, K.C., & Moore, R.D. (2005). Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Medicine, 6, 37-44.
14. Klein, D., Hurley, L.B., Quesenberry, C.P.J., & Sidney, S. (2002). Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? Journal of Acquired Immune Deficiency Syndrome, 30, 471-77.
15. Ledergerber, B., Egger, M., Opravil, M., Telenti, A., Hirschel, B., Battegay, M., Vernazza, P., Sudre, P., Flepp, M., Furrer, H., Francioli, P., & Weber, R. (1999). Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet, 353, 863-68.
16. Lucas, G.M., Chaisson, R.E., & Moore, R.D. (2001). Comparison of initial combination therapy with a single protease inhibitor, ritonavir and sequinavir, or efavirenz [abstract #686]. Infectious Diseases Society of America 39th meeting.
17. Martinez, E., Conget, I., Lozano, L., Casamitjana, R., & Gatell, J.M. (1999). Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS, 13, 805-810.
18. Mary-Krause, M., Cotte, L., Simon, A., Partisani, M., & Costagliola, D. (2003). Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS, 17, 2479-86.
19. Palella, FJ.J., Delaney, K.M., Moorman, A.C., Loveless, M.O., Fuhrer, J., Satten, G.A., Aschman, D.J., & Holmberg, S.D. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine, 338, 853-60.
20. Parenti, D., Ruane, P., Margolis, D., Shepp, D.H., Babinchak, T.J., Van Kempen, A.S., Kauf, T.L., Danehower, S.A., Yau, L., Hessenthaler, S.M., Goodwin, D., Hernandez, J.E.; COL30336 Study Team (2001). The compact quad, combavir/abacavir/efavirenz (COM/ABC/EFV) - preliminary 48-wk results (COL30336) [abstract #697]. Infectious Diseases Society of America 39th meeting.
21. Periard, D., Telenti, A., Sudre, P., Cheseaux, J.J., Halfon, P., Reymond, M.J., Marcovina, S.M., Glauser, M.P., Nicod, P., Darioli, R., & Mooser, V. (1999). Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation, 100, 700-05.
22. Pulvirenti, J., Goodwin, D., & Slater, L., et al. (2001). Simplification of protease inhibitor (PI)-containing HAART regimens with abacavir (ABC) maintains viral suppression and favorable adherence in HIV-1 infected adults (COLA 30305) [abstract #689]. Infectious Diseases Society of America 39th meeting.
23. Rubin, D.B. (1987). Multiple imputation for nonresponse in surveys. New York, NY: John Wiley & Sons, Inc.
24. Sgadari, C., Monini, P., Barillari, G., & Ensoli, B. (2003). Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. Lancet, 4, 537-47.